טקסוטר

מדינה: ישראל

שפה: עברית

מקור: Ministry of Health

מרכיב פעיל:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

זמין מ:

SANOFI - AVENTIS ISRAEL LTD

קוד ATC:

L01CD02

טופס פרצבטיות:

CONCENTRATE FOR SOLUTION FOR INFUSION

מסלול נתינה (של תרופות):

I.V

תוצרת:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

קבוצה תרפויטית:

DOCETAXEL

סממני תרפויטית:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

תאריך אישור:

2012-11-01